Ruxoprubart is under clinical development by NovelMed Therapeutics and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase II drugs for Paroxysmal Nocturnal Hemoglobinuria have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ruxoprubart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ruxoprubart overview

Ruxoprubart (NM-8074) is under development for the treatment of rare diseases involved in complement-mediated disorders including hematology, atypical hemolytic uremic syndrome (aHUS), ocular, C3 glomerulopathy (C3G) (glomerulonephritis), thrombotic microangiopathy, paroxysmal nocturnal hemoglobinuria (PNH), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and inflammatory. It is administered intravenously. The drug candidate acts by targeting complement factor B.

NovelMed Therapeutics overview

NovelMed Therapeutics (NovelMed) is a biotechnology company. The company develops transformative therapies for the treatment of orphan and non-orphan diseases. It offers monoclonal antibodies in the therapeutic areas of paroxysmal nocturnal hemoglobinuria, age related macular degeneration, osteoarthritis, ischemia, arthritis and chronic kidney diseases, among others. NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures. It also conducts research and development for complement-mediated diseases. The company caters to patients, healthcare providers, employees, and investors across the US. NovelMed is headquartered in Cleveland, Ohio, the US.

For a complete picture of Ruxoprubart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.